Key result
Remimazolam provided effective sedation during spinal anaesthesia in elderly patients with a mean successful induction dose of, without altering short-term postoperative cognitive function compared to placebo.
Why the study?
Remimazolam is a potential sedative for non-general anaesthesia in the elderly, but its appropriate sedative dosage and effects on perioperative cognitive function required investigation.
Does remimazolam provide effective sedation and preserve perioperative cognitive function compared to placebo in elderly patients undergoing spinal anaesthesia?
RCT (n=238)
Single-blind
Randomised using a grouping system
Yes
Does remimazolam provide effective sedation and preserve perioperative cognitive function compared to placebo in elderly patients undergoing spinal anaesthesia?
Remimazolam provides effective and safe sedation during spinal anaesthesia in elderly patients without impairing short-term postoperative cognitive function.
Answers are grounded in this paper and cite their sources.
Supports remimazolam for sedation in elderly spinal anesthesia; extends RCT evidence on preserved short-term cognition.
Abstract BACKGROUND Remimazolam, a novel ultra-short-acting benzodiazepine, is a potential sedative for non-general anaesthesia surgery in the elderly. This study aimed to investigate the appropriate sedative dosage of remimazolam and its effects on perioperative cognitive function in elderly patients undergoing non-general anaesthesia surgery. METHODS This multicentre, placebo-controlled trial enrolled 330 elderly patients undergoing non-general anaesthesia procedures at eight centres in China from July 2021 to February 2022, with 238 ultimately completing the study. The primary endpoints were the dose of successful sedation with remimazolam and the changes in perioperative cognitive function. Adverse events were recorded to assess drug safety. RESULTS The induction dose of remimazolam for sedation in spinal anaesthesia in elderly patients was 5.38 mg (95% confidence interval [CI], 5.20 to 5.56), maintained at a rate of 0.223 mg·kg⁻ ¹·h⁻ ¹ (95% CI, 0.201 to 0.237) with no serious adverse effects. Compared with the saline group, there was no statistical difference in the Mini-Mental State Examination scores in the experimental group on Day2 morning (P : 0.886), Day2 afternoon (P : 0.864), and Day7 (P : 0.613), and no statistical difference in the Montreal Cognitive Assessment scores on Day2 morning (P : 0.687), Day2 afternoon (P : 0.827), and Day7 (P : 0.483). CONCLUSIONS Remimazolam besylate is an effective sedative drug during spinal anaesthesia in elderly patients, with a successful induction dose of 5.38 mg (95% CI, 5.20 to 5.56), maintained at a rate of 0.223 mg·kg⁻ ¹·h⁻ ¹ (95% CI, 0.201 to 0.237) and a good safety profile without altering the short-term postoperative cognitive function.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2023) conducted an RCT in Spinal anaesthesia in elderly patients (n=238). Remimazolam vs. 0.9% sodium chloride (placebo) was evaluated on Mini-Mental State Examination (MMSE) score on Day 2 morning (95% CI -0.75 to 0.65, p=0.886). Remimazolam provided effective sedation during spinal anaesthesia in elderly patients with a mean successful induction dose of, without altering short-term postoperative cognitive function compared to placebo.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: